How rare is Ebola hemorrhagic fever?

Ebola hemorrhagic fever is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

How is Ebola hemorrhagic fever diagnosed?

Information about diagnosis is currently limited for this condition.

Are there treatments for Ebola hemorrhagic fever?

Information about treatment is currently limited for this condition.

What are the complications of Ebola hemorrhagic fever?

Ebola hemorrhagic fever can lead to serious complications due to high fever and bleeding. These complications can include organ failure and severe dehydration. The disease has a high mortality rate, which means that many people do not survive after becoming infected.

How does Ebola hemorrhagic fever affect daily life for patients?

Living with Ebola hemorrhagic fever can be very challenging due to the severe symptoms like high fever and bleeding. Patients often need to be isolated to prevent spreading the virus to others. Daily activities can be limited, and patients may require special care and support during their illness.

What is the prognosis for someone diagnosed with Ebola hemorrhagic fever?

The prognosis for Ebola hemorrhagic fever is often serious because of the high mortality rate associated with the disease. Many people who get infected may not survive, and those who do may face long-term health issues. More detailed information on long-term outcomes is currently limited.

Are there specific symptoms unique to Ebola hemorrhagic fever?

The main symptoms of Ebola hemorrhagic fever include high fever and unexplained bleeding. While these are the most recognized symptoms, information about additional specific symptoms is currently limited. It's important to monitor for these symptoms if there is a risk of exposure to the virus.

Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Ebola hemorrhagic fever (EHF) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

Ebola hemorrhagic fever

MONDO:0005737

Also known as:EHFEbolaEbola fever

Find Clinical TrialsTrials

Overview

A viral hemorrhagic fever that is caused by the Ebola virus, which is transmitted by contact with infected animals or humans; it is characterized by high fever, unexplained bleeding, and a high mortality rate.

Treatments1 FDA approved

Clinical Trials12 registered · 2 recruiting

Diagnosis

Biomarker and diagnostic research for Ebola hemorrhagic fever has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for Ebola hemorrhagic fever, including ANSUVIMAB (EBANGA, approved 2020). An additional 9 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

12 clinical trials registered, 2 recruiting. Interventions under study include biologic therapy, other interventions, and drug therapy. Pipeline includes 2 PHASE4, 3 PHASE3, 3 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06126822](https://clinicaltrials.gov/study/NCT06126822)

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:56 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:319218

GARD

Genetic and Rare Diseases Info Center

GARD:2035

Questions for Your Care Team

→What are the benefits and potential side effects of EBANGA for managing Ebola hemorrhagic fever?
→Are any of the 12 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

FAQ

Frequently Asked Questions

Common questions about Ebola hemorrhagic fever

Ebola hemorrhagic fever is a serious viral infection caused by the Ebola virus. It is primarily spread by contact with infected animals or people. This disease is known for causing high fever and unexplained bleeding, and it has a high rate of mortality. Ebola hemorrhagic fever has been a major focus during outbreaks, particularly in some regions of Africa.

Common symptoms of Ebola hemorrhagic fever include high fever and bleeding. Information about additional specific symptoms is currently limited for this condition.

Ebola hemorrhagic fever is caused by the Ebola virus. The virus is transmitted by contact with infected animals or humans. There are no known genetic causes linked to this disease, and exposure to the virus remains the primary risk factor.

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Rintatolimod	Rintatolimod	AIM ImmunoTech Inc.	2022	—	Designated
quinacrine	quinacrine	Collaborations Pharmaceuticals, Inc.	2019	—	Designated
pyronaridine tetraphosphate	pyronaridine tetraphosphate	Collaborations Pharmaceuticals, Inc.	2019	—	Designated
tilorone dihydrochloride	tilorone dihydrochloride	Collaborations Pharmaceuticals, Inc.	2018	—	Designated
Ranpirnase	Ranpirnase	Tamir Biotechnology, Inc.	2017	—	Designated
Monovalent replication-incompetent adenovirus serotype 26 (Ad26) vaccine, AD26.ZEBOV in combination with multivalent replication-defective Modified Vaccinia Ankara (MVA)-Bavarian Nordic (BN) vaccine, MVA-mBN226B	Monovalent replication-incompetent adenovirus serotype 26 (Ad26) vaccine, AD26.ZEBOV in combination with multivalent replication-defective Modified Vaccinia Ankara (MVA)-Bavarian Nordic (BN) vaccine, MVA-mBN226B	Janssen Vaccines and Prevention B.V.	2017	—	Designated
aphidicolin	aphidicolin	Biospherics.net LLC	2016	—	Designated
Remdesivir	Remdesivir	Gilead Sciences, Inc.	2015	—	Designated
monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus	monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus	LeafBio, Inc.	2014	—	Withdrawn

Research Type	Count	% of Total
Laboratory research	77	31%
Research summaries	55	22%
Disease patterns and progression	51	21%
Clinical study results	27	11%
New treatment approaches	19	8%
Other research	8	3%
Testing and diagnosis research	7	3%
Patient case studies	3	1%

Kisho

Ebola hemorrhagic fever

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

‘Walking Ebola’ helps explain why Congo’s outbreak is so hard to stop – and how to treat it | The Straits Times

There's no treatment designed for the Ebola strain ravaging DRC. But now there's hope : NPR

EMA Management Board: highlights of June 2026 meeting

EMA, AMA and African regulatory authorities join forces on Ebola outbreak response

Proposed Data Collection Submitted for Public Comment and Recommendations

Ebola hemorrhagic fever

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is Ebola hemorrhagic fever?

What are the symptoms of Ebola hemorrhagic fever?

What causes Ebola hemorrhagic fever?

How rare is Ebola hemorrhagic fever?

How is Ebola hemorrhagic fever diagnosed?

Are there treatments for Ebola hemorrhagic fever?

What are the complications of Ebola hemorrhagic fever?

How does Ebola hemorrhagic fever affect daily life for patients?

What is the prognosis for someone diagnosed with Ebola hemorrhagic fever?

Are there specific symptoms unique to Ebola hemorrhagic fever?

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

‘Walking Ebola’ helps explain why Congo’s outbreak is so hard to stop – and how to treat it | The Straits Times

There's no treatment designed for the Ebola strain ravaging DRC. But now there's hope : NPR

EMA Management Board: highlights of June 2026 meeting

EMA, AMA and African regulatory authorities join forces on Ebola outbreak response

Proposed Data Collection Submitted for Public Comment and Recommendations